Main Menu

Welcome to BOPA

Latest news from BOPA

Safer Prescribing of Cytotoxic Agents - Academy of Medical Royal Colleges Report April 2015

The Academy of Medical Royal Colleges has published a report entitled: Achieving safer prescription of cytotoxic agents: Academy recommendations

Simon Purcell, BOPA Executive Committee member was involved in the preparation of this guidance. Link -

Prescribing of cytotoxic drugs, immunosuppressant agents and drugs with a narrow therapeutic index by inadequately trained doctors is a longstanding problem. Current systems lack appropriate safeguards and an ongoing and predictable risk to patient safety remains. Recommendations for actions required to address these safety concerns include:

Read More

For details on the forthcoming:

The Introduction to Oncology Course is now fully booked. If you are interested in being waitlisted for this course, please contact Anthony O'Rawe on 01628 897 940.


BOPA Study Days

BOPA are hosting 4 study days with Dr Elaine Vickers on the following topics:

  • The Science of Targeted Cancer Treatments: 19th & 22nd May 2015

  • Targeted Treatments for Haematological: 8th & 9th September 2015

Click here for more information

First Early Access to Medicines (EAMS) Scientific Opinion issued by MHRA

The MHRA has issued its first Early Access to Medicines (EAMS) scientific opinion.

It is for a product called pembrolizumab, used to treat advanced melanoma which has spread or cannot be removed by surgery and has progressed after other treatments.  The MHRA assessment team considered that pembrolizumab had been shown to slow the progression of cancer in a condition where other treatments currently have poor results.

Details of the scientific opinion ( can be found on the MHRA website, as well as background information on EAMS (

For older news items please click here

To pay your conference fees

2013 BOPA Conference fees
2014 BOPA Conference fees